Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Eugene Zhu"'
Autor:
Eugene Zhu, Qi Xia, Libo Sun, John Mascarenhas, Ying Wan, Rami S. Komrokji, Julia Wang, Alessandro M. Vannucchi, Jacqueline Bussolari, Faye Feller, Jean-Jacques Kiladjian, Aleksandra Rizo, Andrew T. Kuykendall
Publikováno v:
Annals of Hematology. 101:139-146
In the MYF2001 trial, treatment of Janus kinase (JAK) inhibitor-relapsed/refractory intermediate-2 or high-risk myelofibrosis (MF) with imetelstat 9.4 mg/kg every 3 weeks demonstrated encouraging median overall survival of 29.9 months. To provide his
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a20c00ca26c0d4a474b98a4025280a89
https://doi.org/10.1007/s00277-021-04683-w
https://doi.org/10.1007/s00277-021-04683-w
Autor:
Eugene Zhu, Maria R. Baer, Dietger Niederwieser, Olatoyosi Odenike, Souria Dougherty, Laurie Sherman, Libo Sun, John Mascarenhas, Aleksandra Rizo, Fei Huang, Rami S. Komrokji, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Bruno Martino, Francesca Palandri, Ying Wan, Jacqueline Bussolari, Ronald Hoffman, Faye Feller, Andreas Reiter, Esther Rose
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(26)
PURPOSE Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall survival (OS) that ranges between 13 and 16 months. Imetelstat, a telomerase i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e652d4947d861536df008fab3efd7dd
https://pubmed.ncbi.nlm.nih.gov/34138638
https://pubmed.ncbi.nlm.nih.gov/34138638
Autor:
Karen Urtishak, Gerhardt Attard, Tokuwa Kanno, Shibu Thomas, Gary E. Mason, Byron Espina, Eugene Zhu, Natalie Hutnick, Mary Guckert, Adam del Corral, Mark Li, Angela Lopez-Gitlitz, Kim Chi, William Kevin Kelly, Evan Y. Yu, Karim Fizazi, Matthew Smith
Publikováno v:
Cancer Research. 82:4133-4133
In the phase 2 GALAHAD study (NCT02854436), the PARP inhibitor (PARPi) niraparib, was evaluated in heavily pre-treated patients with mCRPC and DNA-repair gene defects (DRD) who progressed after androgen-receptor (AR) targeted therapy and taxane-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0436ab830dd2c2c0aaf06cae61599467
https://doi.org/10.1158/1538-7445.am2022-4133
https://doi.org/10.1158/1538-7445.am2022-4133
Autor:
Byron M. Espina, Julie N. Graff, Alex Yu, Peter St. John Francis, Jean Baptiste Lattouf, Fred Saad, Rao N.V.S. Mamidi, Eugene Zhu, Neal D. Shore, Vinny Hayreh, Anasuya Hazra, Branislav Bradic, Marc De Meulder, Arash Rezazadeh Kalebasty, Edwin M. Posadas, Kim N. Chi
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of niraparib with apalutamide or abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC). M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17efd18ebe50c7307e1fdfe4466f9719
https://pubmed.ncbi.nlm.nih.gov/33754187
https://pubmed.ncbi.nlm.nih.gov/33754187
Autor:
Eugene Zhu, Els Vercammen, Kris Deprince, Irakli Kokhreidze, Ilya Safonov, Rubi Li, Lia Abshilava, Mikheil Janjalia, Bruce Kimelblatt, Iryna Litvin, Kuntegowda C. Lakshmaiah, Igor Bondarenko, Ranjan Kumar Mohapatra, Yaroslav Sparyk, Liang Xiu, Brian Leyland-Jones, Beka Samkharadze, Gia Nemsadze, Oksana Tarasova, Sergey Polenkov, Peter Bowers, Vitaliy Smirnov, Vladimir Vladimirov
Publikováno v:
Journal of Clinical Oncology. 34:1197-1207
Purpose An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for metastatic breast cancer. Methods Women with hemoglobin ≤ 11.0 g/dL, receivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85497696e7a65894bb150cb9a146e2b3
https://doi.org/10.1200/jco.2015.63.5649
https://doi.org/10.1200/jco.2015.63.5649
Autor:
Fred Saad, Arash Rezazadeh, Edwin M. Posadas, Julie N. Graff, Shinta Cheng, Eugene Zhu, Neal D. Shore, Vinny Hayreh, Anasuya Hazra, Branislav Bradic, Kim N. Chi, Byron M. Espina
Publikováno v:
Journal of Clinical Oncology. 38:122-122
122 Background: Poly ADP-ribose polymerase (PARP) inhibitor and abiraterone acetate + prednisone (AA+P) has activity in pts with mCRPC regardless of DNA repair gene defects (DRD). Methods: This phase 1b study (Bedivere; NCT02924766) began with a 3+3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faedd6d363f58cf46f6e995464bf4d13
https://doi.org/10.1200/jco.2020.38.6_suppl.122
https://doi.org/10.1200/jco.2020.38.6_suppl.122
Autor:
Eugene Zhu, William Kevin Kelly, Evan Y. Yu, Eleni Efstathiou, Jamie M. Freedman, Byron M. Espina, Primo N. Lara, Fred Saad, Gary Mason, Matthew R. Smith, Shahneen Sandhu, Kim N. Chi, Daniel J. George, Jason S. Simon, Jason Summa, Shinta Cheng, Deborah Ricci, Howard I. Scher, Karim Fizazi, Linda A. Snyder
Publikováno v:
Journal of Clinical Oncology. 38:118-118
118 Background: Niraparib, a highly potent and selective poly (ADP-ribose) polymerase inhibitor (PARPi) received breakthrough designation by US FDA for treatment of pts with BRCA1,2 mutant mCRPC who progressed on taxane and androgen receptor-targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aef722d1c236a93e9b3115654babc106
https://doi.org/10.1200/jco.2020.38.6_suppl.118
https://doi.org/10.1200/jco.2020.38.6_suppl.118
Autor:
William Kevin Kelly, Daniel J. George, Fred Saad, Jason Summa, Shahneen Sandhu, Howard I. Scher, Deborah Ricci, Shinta Cheng, Matthew R. Smith, Eleni Efstathiou, Gary Mason, Karim Fizazi, Evan Y. Yu, J.M. Freedman, Eugene Zhu, Kim N. Chi, Jason S. Simon, Primo N. Lara
Publikováno v:
Annals of Oncology. 30:v884-v885
Background Effective therapies for pts with treatment-refractory mCRPC are an important unmet medical need. Niraparib is a highly selective poly ADP-ribose polymerase (PARP) inhibitor of PARP-1 and PARP-2 DNA-repair polymerases. Methods GALAHAD is an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14fa3e40b4ff28ec497eb8f3ed137ae3
https://doi.org/10.1093/annonc/mdz394.043
https://doi.org/10.1093/annonc/mdz394.043
Autor:
F. Feller, Andrew T. Kuykendall, Aleksandra Rizo, John Mascarenhas, Rami S. Komrokji, Jean-Jacques Kiladjian, Eugene Zhu, Alessandro M. Vannucchi, Ying Wan, Q. Xia, Jacqueline Bussolari, J. Wang
Publikováno v:
HemaSphere. 3:669-670
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45dfc4b1d72a5a97117146d5bbb177b9
https://doi.org/10.1097/01.hs9.0000564088.98639.88
https://doi.org/10.1097/01.hs9.0000564088.98639.88
Autor:
Olga Samoilova, Christopher Enny, João Raposo, Viacheslav Pavlov, Deborah Ricci, Hyeon-Seok Eom, Aleksandra Rizo, Eugene Zhu, Burhan Ferhanoglu, Max S. Topp, Shalini Chaturvedi, Fritz Offner, Osmanov Ea, Helgi van de Velde
Publikováno v:
Blood. 126:1893-1901
This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse lar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f283e646d363aae97d3cc8d45853d40
https://doi.org/10.1182/blood-2015-03-632430
https://doi.org/10.1182/blood-2015-03-632430